Alexa Badalamenti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexa Badalamenti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ang Gao
O’Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Ashley N. Wercholuk
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Caitlin B. Mauer Hall
Division of Cancer Genetics, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication Christine Mai
Clinical Informatics Center University of Texas Southwestern Dallas Texas USA
1 shared publication- Chul Ahn
Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
1 shared publication Cindy Kao
Clinical Informatics Center University of Texas Southwestern Dallas Texas USA
1 shared publication
Latest Publications
- Open Access
- 21 July 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (7) , e70123
Electronic Patient Portals as a Modality for Returning Reclassified Genetic Test Results
Background: Most reclassified genetic test results are clinically inactionable and burdensome for healthcare providers to return to patients. The feasibility of using electronic patient portals (e.g., MyChart) to return reclassified results remains unclear.Methods: Patient and provider initiated MyChart actions were obtained from MyChart data and matched to patient demographic and clinical information using unique patient medical record numbers. Data on who (patient or provider) sent and read these messages and when (date and time) were collected for clinically actionable and inactionable reclassifications.Results: Among 801 patients with 828 reclassified variants in cancer susceptibility genes, 551 had an active MyChart account at the time of reclassification. Patients with active MyChart accounts were less likely to be Hispanic (p < 0.001) compared to other ethnic groups. Of these, 302 (55%) were notified about 308 reclassified results (307 inactionable and 1 actionable) via MyChart messages, and 80% (244/302) read the message within a median time of 3.6 h.Conclusion: We find that it is feasible to return reclassified results via electronic patient portals for most patients, but alternative modalities are still necessary. Unidirectional, low‐touch modalities of recontact can be used to efficiently return the increasing number of inactionable reclassified results.
- 21 July 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (7) , e70123
Open AccessElectronic Patient Portals as a Modality for Returning Reclassified Genetic Test Results
Background: Most reclassified genetic test results are clinically inactionable and burdensome for healthcare providers to return to patients. The feasibility of using electronic patient portals (e.g., MyChart) to return reclassified results remains unclear.Methods: Patient and provider initiated MyChart actions were obtained from MyChart data and matched to patient demographic and clinical information using unique patient medical record numbers. Data on who (patient or provider) sent and read these messages and when (date and time) were collected for clinically actionable and inactionable reclassifications.Results: Among 801 patients with 828 reclassified variants in cancer susceptibility genes, 551 had an active MyChart account at the time of reclassification. Patients with active MyChart accounts were less likely to be Hispanic (p < 0.001) compared to other ethnic groups. Of these, 302 (55%) were notified about 308 reclassified results (307 inactionable and 1 actionable) via MyChart messages, and 80% (244/302) read the message within a median time of 3.6 h.Conclusion: We find that it is feasible to return reclassified results via electronic patient portals for most patients, but alternative modalities are still necessary. Unidirectional, low‐touch modalities of recontact can be used to efficiently return the increasing number of inactionable reclassified results.
- 30 June 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 737-746
Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital
Current guidelines recommend contralateral prophylactic mastectomy (CPM) for women with unilateral breast cancer who have pathogenic/likely pathogenic variants (PV) in high-risk genes, but not for those with variants of uncertain significance (VUS). However, VUS results can cause significant psychosocial distress, which may influence surgical decision-making. In safety-net settings, concerns about insurance coverage and additional social determinants of health may further impact CPM decisions. This study examines surgical trends among patients with early-stage invasive breast cancer who underwent genetic testing before surgery at a safety-net hospital in Dallas, Texas between 2012–2022. We performed a retrospective chart review of 300 early-stage breast cancer patients referred for genetic counseling, analyzing demographics, tumor characteristics, genetic testing results, and treatment. Descriptive statistics and regression analyses were performed. The cohort included 116 patients without mutations (control), 111 with VUS, and 73 with PV. 86.30% of PV patients, 30.63% of VUS patients, and 18.10% of the control group underwent CPM. Multivariate analysis identified PV (OR 26.35, 95% CI: 10.97–63.29, p < 0.0001), VUS (OR 2.35, 95% CI: 1.16–4.77, p = 0.0175), and age at diagnosis (OR 0.963, 95% CI: 0.934–0.993, p = 0.0168) as independent predictors of CPM. These findings suggest that factors beyond established guidelines may influence surgical decision-making, particularly for patients in safety-net hospital settings, underscoring the need for thorough provider and patient counseling.
- 30 June 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 737-746
Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital
Current guidelines recommend contralateral prophylactic mastectomy (CPM) for women with unilateral breast cancer who have pathogenic/likely pathogenic variants (PV) in high-risk genes, but not for those with variants of uncertain significance (VUS). However, VUS results can cause significant psychosocial distress, which may influence surgical decision-making. In safety-net settings, concerns about insurance coverage and additional social determinants of health may further impact CPM decisions. This study examines surgical trends among patients with early-stage invasive breast cancer who underwent genetic testing before surgery at a safety-net hospital in Dallas, Texas between 2012–2022. We performed a retrospective chart review of 300 early-stage breast cancer patients referred for genetic counseling, analyzing demographics, tumor characteristics, genetic testing results, and treatment. Descriptive statistics and regression analyses were performed. The cohort included 116 patients without mutations (control), 111 with VUS, and 73 with PV. 86.30% of PV patients, 30.63% of VUS patients, and 18.10% of the control group underwent CPM. Multivariate analysis identified PV (OR 26.35, 95% CI: 10.97–63.29, p < 0.0001), VUS (OR 2.35, 95% CI: 1.16–4.77, p = 0.0175), and age at diagnosis (OR 0.963, 95% CI: 0.934–0.993, p = 0.0168) as independent predictors of CPM. These findings suggest that factors beyond established guidelines may influence surgical decision-making, particularly for patients in safety-net hospital settings, underscoring the need for thorough provider and patient counseling.